Diagnosis and management of leptomeningeal disease.
Walker
Julie G
JG
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. jgwalker@mdanderson.org
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D055756:Meningeal Carcinomatosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D015995:Prevalence; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D000077157:Sorafenib; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D003606:Dacarbazine; D000077157:Sorafenib; D000077204:Temozolomide